Elsevier

Drug and Alcohol Dependence

Volume 144, 1 November 2014, Pages 148-152
Drug and Alcohol Dependence

Patterns and correlates of non-fatal heroin overdose at 11-year follow-up: Findings from the Australian Treatment Outcome Study

https://doi.org/10.1016/j.drugalcdep.2014.09.001Get rights and content

Highlights

  • Overdose rates amongst the ATOS cohort at 11-year follow-up were examined.

  • By 11-year follow-up, the proportion who had overdosed had risen to 67.5%, 4.9% in the preceding year.

  • Predictors of recent overdose were polydrug use, an overdose history, and more treatment episodes.

  • While overdose rates had declined, overdoses still occurred.

  • Baseline and treatment factors predicted the likelihood of overdose a decade later.

Abstract

Background

Overdose is a major cause of morbidity and mortality amongst opioid users. This paper reported recent non-fatal overdose amongst the Australian Treatment Outcome Study (ATOS) cohort at 11-year follow-up, and characteristics that predict recent overdose.

Methods

Longitudinal cohort, with 431 (70.1%) of the original 615 participants interviewed. Participants were administered the ATOS structured interview, addressing demographics, treatment history, drug use, heroin overdose, criminality, health and psychopathology.

Findings

Mean time since heroin initiation was 20.4 years. By 11-year follow-up, the proportion who had overdosed was 67.5%, and 24.4% had experienced five or more overdoses. In the 12 months preceding 11-year follow-up, 4.9% had overdosed (11.8% of those who had used heroin in that period). Of the 21 participants who had recently overdosed, 20 (95.2%) had overdosed previously, and 19 (90.5%) were not enrolled in a treatment programme at the time. Those who had recently overdosed reported higher levels of use of opiates other than heroin (57.1% vs 24.9%), benzodiazepines (61.9% vs 30.5%,), methamphetamine (38.1% vs 16.8%) and cocaine (19.0% vs 3.7%). They also had exhibited higher levels of heroin use and other drug use at baseline, 12 and 24 month follow-ups.

Conclusions

While the prevalence had declined, overdoses still occurred. A history of overdose and polydrug use patterns continued to provide strong markers for those at continued risk.

Introduction

Opioids make the largest contribution to illicit drug-related death, overdose being the leading cause (Bargagli et al., 2006b, Bird, 2010, Darke, 2011, Darke et al., 2011, Degenhardt et al., 2011, Stenbacka et al., 2010). Fatal outcomes, however, represent a minority of overdoses, with 25–50 non-fatal “near misses” for every fatality (Darke et al., 2003). The ubiquity of overdose amongst users is illustrated by lifetime prevalence, with studies consistently reporting a third to two thirds having overdosed (Backmunda et al., 2009, Bargagli et al., 2006b, Britton et al., 2010, Coffin et al., 2007, Darke et al., 2007, Kerr et al., 2007, Wines et al., 2007). Non-fatal overdose is of clinical significance, as it is associated with harms related to the event itself including anoxic brain damage (Warner-Smith et al., 2001, Warner-Smith et al., 2002), subsequent non-fatal overdose (Coffin et al., 2007, Darke et al., 2007) and subsequent death (Darke et al., 2011).

One of the major findings to emerge over the past few decades has been that overdose is not a random event and, hence, is preventable. A number of specific risk factors have been identified. Firstly, as noted above, a history of overdose strongly predicts future overdoses (Coffin et al., 2007, Darke et al., 2007). Heroin overdoses are also associated with more frequent use, higher levels of dependence and with the injection of the drug (Backmunda et al., 2009, Bargagli et al., 2006b, Britton et al., 2010, Coffin et al., 2007, Darke, 2011, Darke et al., 2007, Kerr et al., 2007, Wines et al., 2007). Overdoses, however, rarely involve only heroin, the overwhelming majority involving the concomitant consumption of other CNS depressants (Backmunda et al., 2009, Britton et al., 2010, Coffin et al., 2007, Kerr et al., 2007, Wines et al., 2007, Darke, 2014, Darke et al., 2010). There is also a substantially elevated risk during a relapse to use after a period of abstinence, such as having been in prison, detoxification or naltrexone maintenance (Davoli et al., 2007, Kerr et al., 2007, Wines et al., 2007, Darke et al., 2002, Farrell and Marsden, 2007, Strang et al., 2003). Finally, most overdoses occur when the person is not enrolled in a long-term, stable drug treatment (Davoli et al., 2007, Kerr et al., 2007, Darke et al., 2010).

There are little data on the long-term natural history of opioid overdose, with almost all research to date being cross-sectional. An exception to this has been the Australian Treatment Outcome Study (ATOS) cohort, recruited in 2001–2002, and interviewed at 12, 24 and 36-month follow-up (Teesson et al., 2008). Typical of such cohorts, at baseline 54% reported having a lifetime history of overdose, 22% having overdosed in the preceding year (Darke et al., 2005). Consistent with reductions in reported heroin use, past 12-month overdose declined across follow-up: 12% (12 months), 9% (24 months) and 8% (36 months; Darke et al., 2005, Darke et al., 2007). While there were marked declines in overdose, 20% had overdosed over the course of the first 36 months. By 2009, 31 (5%) of the cohort were deceased, predominately due to overdose (Darke et al., 2011). Indeed, the only significant predictor of mortality was a history of non-fatal overdose.

In this paper, we present new data on the natural history of overdose amongst the ATOS cohort, examining overdose at 11 years, approximately 20 years since the initiation of heroin use. A number of questions arise. Firstly, what are the levels of lifetime overdose exposure approximately 20 years after first heroin use? What is the prevalence of recent (12 month) overdose at 11-year follow-up, and what are the correlates? Specifically, the study aimed to: (1) determine lifetime and recent overdose prevalence amongst the ATOS cohort at 11-year follow-up; and (2) determine correlates of overdose in the year preceding 11-year interview.

Section snippets

Procedure

The data were collected from the New South Wales component of ATOS. Baseline interviews were conducted between February, 2001 and August, 2002. ATOS is a longitudinal study of heroin users, recruited from randomly selected treatment agencies delivering methadone/buprenorphine maintenance treatment (MT) (n = 201), drug free residential rehabilitation (RR) (n = 133) or detoxification (DTX) (n = 201). Subjects were recruited from 19 agencies treating heroin dependence in the greater Sydney region,

Cohort characteristics

The initial cohort consisted of 615 current heroin users, full details of which may be found in Ross et al. (2005). At 11-year follow-up, 431 (70.1%) participants were interviewed, 63 (10.2%) were known to be deceased, 7 (1.1%) were incarcerated and 42 (6.8%) did not wish to participate. A further 21 (3.4%) were confirmed to be alive, but were not interviewed due to repeated cancellations. Overall, we could account for 91.6% of participants. The mean age at 11-year follow-up was 40.0 years (SD

Discussion

To our knowledge, this is the first data to be presented on overdose patterns amongst a cohort some 20 years after heroin initiation. By 11-year follow-up, the proportion who had ever overdosed had risen to over two thirds, with over 2,000 lifetime overdoses reported. While the proportion who had recently overdosed consistently declined across follow-ups, one in 20 had recently overdosed, and one in 10 had done so in the past three years. The correlates of recent overdose, however, remained

Role of funding source

This research was funded by the National Health and Medical Research Council. The NHMRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Contributors

Professors Darke conducted the statistical analyses and write-up of the paper. Professors Teesson and Darke, Associate Professors Mills, Slade; Burns and Dr Ross were Chief Investigators on the project. Dr Marel was the project coordinator, involved in data collection and entry. All authors contributed to and have approved the final manuscript.

Conflict of interest

None to declare.

Acknowledgements

This research was funded by a National Health and Medical Research Council project (grant number 1009934), and NHMRC Fellowships to Maree Teesson and Katherine Mills. The National Drug and Alcohol Research Centre at the University of NSW is supported by funding from the Australian Government. The authors wish to thank Joanne White, Sonja Memedovic, Sarah Ellis, Philippa Ewer, Louise Mewton, the original ATOS research team and all participating agencies.

References (41)

  • A.M. Bargagli et al.

    VEdeTTE, a longitudinal study on effectiveness of treatments for heroin addiction in Italy: study protocol and characteristics of study population

    Subst. Use Misuse

    (2006)
  • A.M. Bargagli et al.

    Drug-related mortality and its impact on adult mortality in eight European countries

    Eur. J. Public Health

    (2006)
  • S.M. Bird

    Over 1200 drugs-related deaths and 190,000 opiate-users-years of follow-up, relative risks by sex and age group

    Addict. Res. Theory

    (2010)
  • T.J. Cicero et al.

    The changing face of heroin use in the United States: a retrospective analysis of the past 50 years

    JAMA Psychiatry

    (2014)
  • P.O. Coffin et al.

    Identifying injecting drug users at risk of nonfatal overdose

    Acad. Emerg. Med.

    (2007)
  • S. Darke

    Opioid overdose and the power of old myths, what we thought we knew, what we do know, and why it matters

    Drug Alcohol Rev.

    (2014)
  • S. Darke

    The Life of the Heroin User: Typical Beginnings, Trajectories and Outcomes

    (2011)
  • S. Darke et al.

    Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: the opiate treatment index

    Br. J. Addict.

    (1992)
  • S. Darke et al.

    Hair morphine concentrations of fatal heroin overdose cases and living heroin users

    Addiction

    (2002)
  • S. Darke et al.

    The ratio of non-fatal to fatal overdose

    Addiction

    (2003)
  • Cited by (38)

    • Periods of altered risk for non-fatal drug overdose: a self-controlled case series

      2021, The Lancet Public Health
      Citation Excerpt :

      Even though our study examined opioid and benzodiazepine use separately, our results emphasise the high risk associated with benzodiazepine use, suggesting that caution is needed when prescribing benzodiazepines for people who are concurrently prescribed opioid medications, who might engage in illicit opioid use, or who fulfil both criteria. Not only can polydrug use increase the risk of overdose,6 treatments such as naloxone might also be less effective in the context of polydrug overdose.44 Prescribing practices need to consider the risk associated with the concurrent use of benzodiazepines and opioids, and overdose prevention and treatment programmes need to ensure that they can recognise and respond appropriately to polydrug overdoses.

    • Impact of benzodiazepines and polysubstance status on repeat non-fatal drug overdoses

      2021, Journal of Substance Abuse Treatment
      Citation Excerpt :

      While studies have described factors associated with fatal and nonfatal overdoses in the state (Golladay et al., 2020; Krishnaswami et al., 2020; Tennessee Department of Health, 2019), research has not explored factors leading to repeat overdose, and the role of polysubstance use in repeat overdose. Repeat overdoses are associated with substantial morbidity and increased risk of death (Darke et al., 2014; Zibbell et al., 2019). The national estimated burden of opioid overdoses and dependence in 2013 was $78.5 billion, with 25% of the cost falling on the public through health care, treatment, and criminal justice costs (Florence et al., 2016).

    View all citing articles on Scopus
    View full text